Related references
Note: Only part of the references are listed.Recurrence Patterns After Hepatectomy of Hepatocellular Carcinoma: Implication of Milan Criteria Utilization
Toshiya Kamiyama et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors
J. Qiao et al.
GENE THERAPY (2008)
Synergistic Antitumor Effects of Transarterial Viroembolization for Multifocal Hepatocellular Carcinoma in Rats
Jennifer Altomonte et al.
HEPATOLOGY (2008)
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy
Lan Wu et al.
HUMAN GENE THERAPY (2008)
Immune response in the absence of neurovirulence in mice infected with M protein mutant vesicular stomatitis virus
Maryam Ahmed et al.
JOURNAL OF VIROLOGY (2008)
Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for Cancer
Timothy Kottke et al.
MOLECULAR THERAPY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Combination Therapy with S-1 and Pegylated Interferon Alpha for Advanced Hepatocellular Carcinoma
Kazuomi Ueshima et al.
ONCOLOGY (2008)
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
Thi Lien-Anh Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice
David Cooper et al.
JOURNAL OF VIROLOGY (2008)
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
Apollina Goel et al.
BLOOD (2007)
Viruses as anticancer drugs
Stephen J. Russell et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates
J. Erik Johnson et al.
VIROLOGY (2007)
Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma
Edward J. Shin et al.
LARYNGOSCOPE (2007)
Effects of intravenously administered recombinant vesicular stomatitis virus (VSVΔM51) on Multifocal and invasive gliomas
XueQing Lun et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector
David K. Clarke et al.
SPRINGER SEMINARS IN IMMUNOPATHOLOGY (2006)
Type 1 interferons and the virus-host relationship:: A lesson in detente
A García-Sastre et al.
SCIENCE (2006)
A comparison of the antitumor effects of interferon-α and β on human hepatocellular carcinoma cell lines
M Murata et al.
CYTOKINE (2006)
VSV-tumor selective replication and protein translation
GN Barber
ONCOGENE (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Vesicular stomatitis virus: re-inventing the bullet
BD Lichty et al.
TRENDS IN MOLECULAR MEDICINE (2004)
Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer
O Ebert et al.
CANCER RESEARCH (2004)
Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages
IS Novella et al.
JOURNAL OF VIROLOGY (2004)
Vesicular stomatitis virus as an oncolytic vector
GN Barber
VIRAL IMMUNOLOGY (2004)
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
DF Stojdl et al.
CANCER CELL (2003)
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity
M Obuchi et al.
JOURNAL OF VIROLOGY (2003)
Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus
SA Kopecky et al.
JOURNAL OF VIROLOGY (2001)